Last --
Change Today 0.00 / 0.00%
Volume 0.0
1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, is engaged in the research, development, manufacture, and sale of bio-pharmaceutical products in the People’s Republic of China. The company offers genetic engineering drugs, which include recombinant tissue type plasminogen activator for heart infarction; recombinant human lymphotoxin a-derivatives, a phase II clinical trial product for tumors; recombinant human tumor necrosis recipient Fc fusion protein (Etanercept) and high bio-activity recombinant human TNF receptor for the treatment of arthritis; PTH that is in phase I clinical trial product for osteoporosis; CD30-MMAE and Avastin, which are in pre-clinical study for treating tumor; Anti-sclerostin mab that is in pre-clinical study for the treatment of Osteoporosis; and PCSK9, which is in pre-clinical study for hypercholesterolemia. It also provides photodynamic therapy drugs comprising Hemoporfin for the treatment of port wine stain; Duteroporphyrin, a phase I clinical trial product for treating tumors; and Aminolevulinic acid that is in phase I clinical trial for the treatment of cervical diseases infected by HPV, as well as in pre-clinical study for treating acne, brain gliomas, and basal cell carcinoma diseases. In addition, the company offers liposomal drugs, including Libod, a doxorubicin liposome injection for treating tumors; Vincristine sulphate liposome, which is in phase–I clinical trial for treating tumors; Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical study for the treatment of tumors; and Xenon liposome, which is in pre-clinical study for treating strokes. Further, it provides Antenatal Screening Diagnostic Reagent for down’s syndrome; and Nifeviroc that is in research for AIDS prevention, as well as sells medical diagnostic products. It has a strategic agreement with Shanghai Pharmaceutical Co., Ltd. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

470 Employees
Last Reported Date: 09/2/14
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Co-Founder, Chairman, General Manager and Cha...
Total Annual Compensation: CNY2.0M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.2M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.2M
Compensation as of Fiscal Year 2013.

shanghai fudan-zhangjiang-h (1349) Key Developments

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. to Approve Amendments to the Articles of Association

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. at its annual general meeting held on 30 May 2014, resolved to approve the amendments to the articles of association of the company in respect of Articles 7, 97, 117 and 118, and to authorize the Board to make all necessary applications, approvals, registrations and filings and other related matters (if any) in connection with the amendments to the Articles of Association including all necessary revisions as required by the competent authorities of the PRC.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Announces Management Changes

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced that Ms. Fang Jing has not offered herself for re-election to the fifth session of the Board upon expiry of her term of office. Accordingly, she ceased to be non-executive Director upon conclusion of the AGM. Mr. Pan Fei and Mr. Cheng Lin have not offered themselves for re-election to the fifth session of the board upon expiry of their respective terms of office. Accordingly, they ceased to be independent non-executive Directors upon conclusion of the AGM. Mr. Chen Kai Xian has been newly appointed as independent non-executive Director of the fifth session of the board effective upon conclusion of the AGM.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Receives Clinical Trial Approval from CFDA for High Bio-Activity Recombinant Human TNF Receptor

The board of the directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced that the Company has obtained clinical trial approval issued by China Food and Drug Administration for high bio-activity recombinant human TNF receptor. The approval No is 2014L00653. The project will enter into the clinical trial phase I. High bio-activity recombinant Human TNF receptor is intended to be used for the treatment of self-immunological diseases, such as Arthritis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1349:HK $7.59 HKD +0.01

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 57.9x
Price/Sales 13.6x
Price/Book 9.8x
Price/Cash Flow 58.6x
TEV/Sales 12.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.